The company said clearance marks an important step forward in the development of its NeedleVue and OnPoint technologies. These work in tandem with the NeedleVue LC1 ultrasound system to transform image-guided procedures.

DeepSight says NeedleVue can go beyond traditional imaging by combining high-resolution ultrasound with intelligent instrument tracking. This enables clinicians to pinpoint targets, navigate complex anatomy and perform interventions with sub-millimeter accuracy.

The company says its platform could apply to biopsies, tumor ablation, targeted drug delivery, vascular access and structural heart. It could also apply to spinal therapies, neuromodulation, minimally invasive surgery and robotic procedures. The therapy could reduce risk, radiation exposure and recovery time for patients worldwide.